TOKYO UNIVERSITY OF SCIENCE TAKAHASHI TSUJI'S LABORATORY
Members/Glycobiotechnology
- [ Group leader ]
Visiting Professor Katsunari Tezuka, PhD - Visiting Professor, Research Institute for Science and Technology, Tokyo University of Science
- Principal Researcher of Glycotechnology Laboratory, Otsuka Chemical Co, Ltd.
- Researcher Masatoshi Maeda, MSc
- Glycotechnology Laboratory,
Otsuka Chemical Co, Ltd. - Doctoral course, Material Science and Production Engineering, Graduate School of Science and Engineering, Kagoshima University, Graduated
- Researcher Keisuke Tazuru, MSc
- Glycotechnology Laboratory,
Otsuka Chemical Co, Ltd. - Doctoral course, Kyoto University Graduate School of Biostudies Department of Animal, Development and Physiology Laboratory of Immunobiology, Graduated
- Naoki Kamei, MSc
- Biological Science and Technology, Graduate School of Industrial Science and Technology, Tokyo University of Science, PhD student D3
- Masahiro Kojima, BSc
- Biological Science and Technology, Graduate School of Industrial Science and Technology, Tokyo University of Science, MSc student M2
- Yuriko Saiki, BSc
- Biological Science and Technology, Graduate School of Industrial Science and Technology, Tokyo University of Science, MSc student M2
- Technical Assistant Ai Himeno, MSc
- Glycotechnology Laboratory,
Otsuka Chemical Co, Ltd.
- Technical Assistant Kyoko Shimomura-Isumi
- Glycotechnology Laboratory,
Otsuka Chemical Co, Ltd.
The Glycobiotechnology team has been researching the biological roles of glycans through the evaluation of chemically synthesized glycoproteins. Our library of 35 human biantennary complex-type glycans is a useful tool to examine specific glycan structure-glycoprotein activity relationships and to investigate the biological function of glycans. Prof. Kajihara’s group has been studying a new chemical synthesis technology for glycoproteins, which enables us to produce structurally identified biopharmaceuticals with one particular glycan structure. The Glycotechnology Laboratory of Otsuka Chemical Co., Ltd. also has been developing the mass production technologies for glycans, glycopeptides, and glycoproteins which improve upon current manufacturing methods by using mammalian cell culture that produce a mixture of different glycan structures called glycoform. We aim at a paradigm shift in the manufacturing of glycoprotein pharmaceuticals through the creation of highly-functional biopharmaceuticals with an optimized glycan structure and to establish a new manufacturing technology.
